AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales

AbbVie has tacked down its first regulatory approval for risankizumab as it begins what it hopes is a global rollout for the psoriasis drug in 2019 with a plan to quickly attain megablockbuster status.